AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by ITS nested PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum samples tested by MSG PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum samples tested by mtLSU rRNA nested PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum samples tested by ITS nested PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: COMPARATOR
Intervention: Control group (immunocompetent individuals)
Number of subjects: 145
Study 16377394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 1846
Study 16377394 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose hemodialysis
Number of subjects: 1846
Study 16377394 — intervention group
Group type: COMPARATOR
Intervention: High-dose hemodialysis
Number of subjects: 1846
Study 12783106 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy (1 mg/kg twice daily for 14 days, then randomized to 1.0 mg/kg vs. 1.5 mg/kg once daily)
Number of subjects: 60
Study 12783106 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy
Number of subjects: 60
Study 12783106 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin as a bridge to warfarin (target INR 2.0-3.0)
Number of subjects: 60
Study 12783106 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin as a bridge to warfarin
Number of subjects: 60
Study 10993961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with mitomycin C (15 mg/M(2) on the first and sixth week of radiotherapy)
Number of subjects: 160
Study 10993961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with mitomycin C
Number of subjects: 160
Study 10993961 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 160
Study 8791049 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2 orally daily for 2 years
Number of subjects: 437
Study 8791049 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Number of subjects: 437
Study 8791049 — intervention group
Group type: COMPARATOR
Intervention: no treatment (observation only)
Number of subjects: 437
Study 1538722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg per day given orally)
Number of subjects: 189
Study 1538722 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (1 mg per kilogram of body weight per week given intravenously)
Number of subjects: 189
Study 1538722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 189
Study 1538722 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 189
Study 6548925 — intervention group
Group type: EXPERIMENTAL
Intervention: Almax (hydrated aluminium‐magnesium hydroxycarbonate)
Number of subjects: 10
Study 6548925 — intervention group
Group type: COMPARATOR
Intervention: Antacid A (aluminium‐magnesium hydroxide codried gel, aluminium hydroxide, calcium carbonate)
Number of subjects: 10
Study 6548925 — intervention group
Group type: EXPERIMENTAL
Intervention: Almax
Number of subjects: 10
Study 6548925 — intervention group
Group type: COMPARATOR
Intervention: Antacid A
Number of subjects: 10
Study 31502349 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy (MIRH) with no-touch isolation technique
Number of subjects: 109
Study 30264287 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐peripheral punches
Number of subjects: 9
Study 30264287 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐radial cuts
Number of subjects: 9
Study 30264287 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltese cross
Number of subjects: 9
Study 30264287 — intervention group
Group type: COMPARATOR
Intervention: Control (pre‐preparation)
Number of subjects: 9
Study 26541099 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Dot bystander intervention
Number of subjects: 7111
Study 24661128 — intervention group
Group type: EXPERIMENTAL
Intervention: GFD-oats
Number of subjects: 71
Study 24661128 — intervention group
Group type: COMPARATOR
Intervention: GFD-std
Number of subjects: 71
Study 22214492 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal digital assistants intervention promoting walking
Number of subjects: 14
Study 22214492 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived access to supportive environments
Number of subjects: 14
Study 22214492 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived environmental barriers
Number of subjects: 14
Study 19215577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg qd
Number of subjects: 42
Study 19215577 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study 16498265 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (NO synthase inhibitor)
Number of subjects: 0
Study 16498265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (cGMP enhancer)
Number of subjects: 0
Study 16498265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16498265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (prostaglandin inhibitor)
Number of subjects: 0
Study 16498265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (H1 receptor antagonist)
Number of subjects: 0
Study 14623703 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-CD4 20 mg
Number of subjects: 85
Study 14623703 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-CD4 80 mg
Number of subjects: 85
Study 14623703 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-CD4 160 mg
Number of subjects: 85
Study 14623703 — intervention group
Group type: EXPERIMENTAL
Intervention: HuMax-CD4 280 mg
Number of subjects: 85
Study 14623703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10922312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-D(3) group (n = 39)
Number of subjects: 51
Study 10922312 — intervention group
Group type: EXPERIMENTAL
Intervention: Active forms of vitamin D supplementation in the low-D(3) group
Number of subjects: 51
Study 10922312 — intervention group
Group type: COMPARATOR
Intervention: Normal-D(3) group (n = 12)
Number of subjects: 51
Study 10922312 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 51
Study 8938009 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-blind group
Number of subjects: 0
Study 1448266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone
Number of subjects: 120
Study 1448266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3901936 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg prostaglandin E2 (PGE2) gel
Number of subjects: 14
Study 3901936 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study 31442003 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (11% THC; <1% CBD)
Number of subjects: 14
Study 31442003 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD equivalent cannabis (11% THC; 11% CBD)
Number of subjects: 14
Study 31442003 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis (<1% THC; <1% CBD)
Number of subjects: 14
Study 29271843 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with positive end-expiratory pressure of at least 5 cm H2O
Number of subjects: 219
Study 29271843 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 219
Study 26993471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed incentive condition (usual invitation letter, including a voucher for £10 if they attend their appointment)
Number of subjects: 1000
Study 26993471 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic incentive condition (invitation letter, including a voucher for a 1 in 100 chance of winning £1000 if they attend their appointment)
Number of subjects: 1000
Study 26993471 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual invitation letter)
Number of subjects: 1000
Study 23981321 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-learning training, 2-weekly sessions across 10 weeks
Number of subjects: 5
Study 23163988 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 88
Study 23163988 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 88
Study 20812958 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplement (1000 mg/d for 12 weeks)
Number of subjects: 36
Study 20812958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-carnitine supplement)
Number of subjects: 36
Study 17926113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 46
Study 17926113 — intervention group
Group type: COMPARATOR
Intervention: Scleral Buckling
Number of subjects: 46
Study 16369725 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted logistic regression approach to adjust odds ratios
Number of subjects: 0
Study 16369725 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnostic technique for hip BMD and deformity severity
Number of subjects: 0
Study 12796586 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE patching
Number of subjects: 180
Study 12796586 — intervention group
Group type: COMPARATOR
Intervention: Hemashield patching
Number of subjects: 180
Study 10948088 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg/kg per hour)
Number of subjects: 26
Study 10948088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1 to 3 mg/h)
Number of subjects: 26
Study 10948088 — intervention group
Group type: COMPARATOR
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 26
Study 10948088 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 26
Study 8980592 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over three days)
Number of subjects: 77
Study 8980592 — intervention group
Group type: COMPARATOR
Intervention: Maloprim (6.25 mg pyrimethamine + 50 mg dapsone for children under 10 years, and 12.5 mg pyrimethamine + 100 mg dapsone for children 10 or more years old as a single dose)
Number of subjects: 77
Study 1419440 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40
Study 1419440 — intervention group
Group type: COMPARATOR
Intervention: Face mask and Guedel airway
Number of subjects: 40
Study 3914621 — intervention group
Group type: COMPARATOR
Intervention: Daily administration of retinoids
Number of subjects: 0
Study 3914621 — intervention group
Group type: COMPARATOR
Intervention: Administration of retinoids
Number of subjects: 0
Study 3914621 — intervention group
Group type: COMPARATOR
Intervention: Folic acid administration
Number of subjects: 0
Study 31580693 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel mask
Number of subjects: 200
Study 31580693 — intervention group
Group type: COMPARATOR
Intervention: Baska mask
Number of subjects: 200
Study 31580693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both I-gel and Baska masks
Number of subjects: 200
Study 28953669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group (ULS group; n=20)
Number of subjects: 40
Study 28953669 — intervention group
Group type: COMPARATOR
Intervention: Oxygenation group (OXY group; n=20)
Number of subjects: 40
Study 28953669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after pulmonary recruitment
Number of subjects: 40
Study 25395078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscope‐assisted 'Mini‐Perc' technique
Number of subjects: 72
Study 25395078 — intervention group
Group type: COMPARATOR
Intervention: Modified open surgery
Number of subjects: 72
Study 24046526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 122
Study 24046526 — intervention group
Group type: COMPARATOR
Intervention: Modified supine position
Number of subjects: 122
Study 23272437 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 90
Study 23272437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 90
Study 23272437 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 90
Study 18297248 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 12
Study 18297248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17219216 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 and 50 mg)
Number of subjects: 14
Study 17219216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15378567 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term radiotherapy
Number of subjects: 1304
Study 15378567 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing mucinous carcinoma
Number of subjects: 1304
Study 11993408 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium losartan 50 mg per day
Number of subjects: 19
Study 9323736 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual training
Number of subjects: 30
Study 9323736 — intervention group
Group type: COMPARATOR
Intervention: Reading (placebo)
Number of subjects: 30
Study 9323736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 8188888 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcitriol (3 micrograms/gm) applied twice daily for 6 weeks
Number of subjects: 18
Study 8188888 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate (500 micrograms/gm)
Number of subjects: 18
Study 3796920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of prostaglandin E1 analogue (ONO-802)
Number of subjects: 121
Study 3796920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 121
Study 30866893 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination (94.2% reported vaccination; 4.7% with 2 doses, 58.1% with 3 doses, 37.2% took a booster)
Number of subjects: 306
Study 30866893 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (OR=4.24), lack of HBV vaccination (OR=7.42), working in high HBV incidence province (OR=2.69)
Number of subjects: 306
Study 30866893 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of safety devices (SD) (86.3% usage)
Number of subjects: 306
Study 30866893 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle recapping (35.9% participants)
Number of subjects: 306
Study 30866893 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-reporting of sharp injuries (SIs) (80.0% incidents not reported)
Number of subjects: 306
Study 30127247 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (752 mg)
Number of subjects: 22
Study 30127247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (800 mg corn starch)
Number of subjects: 22
Study 26961597 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of tranexamic acid (TXA) mixed in 100 mL normal saline
Number of subjects: 108
Study 26961597 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of normal saline
Number of subjects: 108
Study 25200415 — intervention group
Group type: EXPERIMENTAL
Intervention: QGE031 (2 mg/kg)
Number of subjects: 183
Study 25200415 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 183
Study 25200415 — intervention group
Group type: COMPARATOR
Intervention: QGE031 (0.1-10 mg/kg) or placebo (IV)
Number of subjects: 183
Study 25200415 — intervention group
Group type: COMPARATOR
Intervention: QGE031 (0.2-4 mg/kg) or placebo (SC)
Number of subjects: 183
Study 25200415 — intervention group
Group type: EXPERIMENTAL
Intervention: QGE031 (10 mg/kg)
Number of subjects: 183
Study 22265698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4657
Study 22265698 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4657
Study 21166111 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily Tacrolimus Extended Release (Tac ER)
Number of subjects: 18
Study 21166111 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily Cyclosporine (CsA)
Number of subjects: 18
Study 17934668 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise three times per week for 20 weeks
Number of subjects: 40
Study 17934668 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling and psychological support
Number of subjects: 40
Study 16644634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for 12 weeks)
Number of subjects: 42
Study 12048178 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert orienting of attention paradigm in pointing task (valid, neutral, invalid conditions)
Number of subjects: 0
Study 12048178 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert orienting of attention paradigm in detection task (key-pressing)
Number of subjects: 0
Study 9869176 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (100 microg daily)
Number of subjects: 36
Study 9869176 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg twice daily)
Number of subjects: 36
Study 9869176 — intervention group
Group type: COMPARATOR
Intervention: Control (non-supplemented)
Number of subjects: 36
Study 7637854 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Reaction Time (SRT) task
Number of subjects: 21
Study 2517495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxindanac 200 mg thrice daily
Number of subjects: 0
Study 2517495 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g thrice daily (positive control)
Number of subjects: 0
Study 194506 — intervention group
Group type: EXPERIMENTAL
Intervention: EG626 (cAMP phosphodiesterase inhibitor)
Number of subjects: 23
Study 31515921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral IgG
Number of subjects: 16
Study 31515921 — intervention group
Group type: COMPARATOR
Intervention: Non-oral IgG
Number of subjects: 16
Study 28719709 — intervention group
Group type: EXPERIMENTAL
Intervention: Received the book for free
Number of subjects: 112
Study 28719709 — intervention group
Group type: COMPARATOR
Intervention: Recommended to purchase the book
Number of subjects: 112
Study 28719709 — intervention group
Group type: EXPERIMENTAL
Intervention: General cohort
Number of subjects: 112
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (2 mg/kg - 50 mg/kg)
Number of subjects: 41
Study 27077121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (30 mg/kg)
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (50 mg/kg)
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (2% coverage)
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (6% coverage)
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (2% coverage for elderly)
Number of subjects: 41
Study 27077121 — intervention group
Group type: EXPERIMENTAL
Intervention: VIS410 (6% coverage for elderly)
Number of subjects: 41
Study 24416316 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Site Support (OSS)
Number of subjects: 36
Study 24416316 — intervention group
Group type: COMPARATOR
Intervention: Control (arm B)
Number of subjects: 36
Study 22012970 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356
Study 22012970 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356
Study 22012970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 19254816 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup (0.14 g fructooligosaccharides/kg/day)
Number of subjects: 100
Study 19254816 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup (0.29 g fructooligosaccharides/kg/day)
Number of subjects: 100
Study 17197807 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count and plasma HIV‐1 RNA (pVL)‐guided treatment interruptions (GTI)
Number of subjects: 201
Study 17197807 — intervention group
Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (control group)
Number of subjects: 201
Study 15976210 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of hyperbaric ropivacaine 0.5% (group Ropi‐7.5, n = 31)
Number of subjects: 91
Study 15976210 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐5, n = 30)
Number of subjects: 91
Study 15976210 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐7.5, n = 30)
Number of subjects: 91
Study 16900603 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodative intraocular lenses (IOLs)
Number of subjects: 0
Study 16900603 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lenses (IOLs)
Number of subjects: 0
Study 16900603 — intervention group
Group type: COMPARATOR
Intervention: Multifocal intraocular lenses (IOLs)
Number of subjects: 0
Study 10528287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) administered orally at 1 g twice daily
Number of subjects: 16
Study 10528287 — intervention group
Group type: COMPARATOR
Intervention: Systemic cyclosporin A (CSA) with dosage varying between 100 and 500 mg daily based on blood trough levels of 120-150 ng/ml
Number of subjects: 16
Study 8895005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose interferon-alpha 2b 3 MU thrice weekly for 1 year
Number of subjects: 95
Study 8895005 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated dose interferon starting at 5 MU thrice weekly for 1 year
Number of subjects: 95
Study 8895005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 95
Study 2071726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0
Study 2071726 — intervention group
Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 0
Study 6133481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg
Number of subjects: 94
Study 6133481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 94